Lyngby, Denmark

Tine Elisabeth Gottschalk Bøving


Average Co-Inventor Count = 7.9

ph-index = 2

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 2012-2014

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Tine Elisabeth Gottschalk Bøving: Innovator in Pharmaceutical Compositions

Introduction

Tine Elisabeth Gottschalk Bøving is a notable inventor based in Lyngby, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the development of stable formulations for peptides. With a total of 2 patents, his work has the potential to impact the treatment of various medical conditions.

Latest Patents

Bøving's latest patents include innovative formulations aimed at improving the efficacy of peptide-based treatments. One of his patents focuses on stable pharmaceutical compositions comprising insulinotropic peptides. Another patent addresses soluble pharmaceutical compositions for parenteral administration, which include a GLP-1 peptide and an insulin peptide designed for short-term action in the treatment of diabetes and bulimia. These advancements highlight his commitment to enhancing therapeutic options for patients.

Career Highlights

Tine Elisabeth Gottschalk Bøving is associated with Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care and other chronic conditions. His work at Novo Nordisk has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Bøving has collaborated with esteemed colleagues such as Svend Ludvigsen and Morten Schlein. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Tine Elisabeth Gottschalk Bøving is a distinguished inventor whose work in pharmaceutical compositions is paving the way for new treatment options. His contributions to the field are invaluable and demonstrate the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…